Measuring Herpes Zoster and PHN Associated Burden of Illness and Health Care Utilization Costs in Thailand

Measuring Herpes Zoster and Post-Herpetic Neuralgia Associated Burden of Illness and Health Care Utilization and Costs in Thailand

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00526864

Enrollment

180

Registered

2007-09-10

Start date

2007-05-31

Completion date

2008-07-31

Last updated

2015-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Herpes Zoster

Keywords

Burden of Illness for Herpes zoster in Thailand.

Brief summary

Total 7 institutions will be recruited i.e. Clinical Infectious Disease Research Unit Department of Clinical Tropical Medicine, Faculty of Tropical Medicine Mahidol University,Bamrasnaradura Infectious Disease Institute ,Pramonkutklao Hospital,Rajavithi Hospital,NationalCancerInstitute,Institute of Dermatology,Raj Pracha Samasai Institute OBJECTIVES * Measure the burden of illness due to herpes zoster (Zoster) and post-herpetic neuralgia (PHN) (severity and duration); * Assess the quality of life (QoL) and quality adjusted life years (QALY) lost due to Zoster and PHN; * Describe health care resource utilization associated with Zoster and PHN; * Describe the direct and indirect costs per case of Zoster and PHN

Detailed description

This will be a prospective cohort study of patients presenting with Zoster rash in 7 specialized institutions in Thailand. Subjects will be entered in the cohort at the time of presentation with Zoster rash. After the baseline assessment (day 0) that will be conducted at the investigator's office there will be 4 assessments (prospective part of the study) that will be conducted at day 7, month 1, month 3 and month 6. We expect that there will be approximately 150 patients included in the study cohort. Cohort assembly will take place between April 2007 and October 2007. The study will be conducted in 3 groups Eligible patients for each group will include * Group A: Both male and female patients ≥ 50 years of age with Zoster rash. * Group B: Both HIV infected male and female patients ≥ 20 years of age with Zoster rash. * Group C: Both Oncology male and female patients ≥ 20 years of age who on chemotherapy with Zoster rash. Key exclusion criteria includes patient who refuses to sign informed consent.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Physician confirmed diagnosis of Zoster rash * of onset of Zoster rash must be documented in the patient's chart. * Patient is capable of understanding the study and the content of the consent form and has agreed to participate in the study by signing the informed consent. * Patient will be available for the study follow up period

Exclusion criteria

* no specific

Countries

Thailand

Outcome results